• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心肌细胞程序性坏死:线粒体、死亡受体及其他。

Programmed necrosis in cardiomyocytes: mitochondria, death receptors and beyond.

机构信息

State Key Laboratory of Membrane Biology, Institute of Molecular Medicine, Peking University, Beijing, China.

出版信息

Br J Pharmacol. 2019 Nov;176(22):4319-4339. doi: 10.1111/bph.14363. Epub 2018 Jun 25.

DOI:10.1111/bph.14363
PMID:29774530
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6887687/
Abstract

Excessive death of cardiac myocytes leads to many cardiac diseases, including myocardial infarction, arrhythmia, heart failure and sudden cardiac death. For the last several decades, most work on cell death has focused on apoptosis, which is generally considered as the only form of regulated cell death, whereas necrosis has been regarded to be an unregulated process. Recent findings reveal that necrosis also occurs in a regulated manner and that it is closely related to the physiology and pathophysiology of many organs, including the heart. The recognition of necrosis as a regulated process mandates a re-examination of cell death in the heart together with the mechanisms and therapy of cardiac diseases. In this study, we summarize the regulatory mechanisms of the programmed necrosis of cardiomyocytes, that is, the intrinsic (mitochondrial) and extrinsic (death receptor) pathways. Furthermore, the role of this programmed necrosis in various heart diseases is also delineated. Finally, we describe the currently known pharmacological inhibitors of several of the key regulatory molecules of regulated cell necrosis and the opportunities for their therapeutic use in cardiac disease. We intend to systemically summarize the recent progresses in the regulation and pathological significance of programmed cardiomyocyte necrosis along with its potential therapeutic applications to cardiac diseases. LINKED ARTICLES: This article is part of a themed section on Mitochondrial Pharmacology: Featured Mechanisms and Approaches for Therapy Translation. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.22/issuetoc.

摘要

心肌细胞的过度死亡会导致许多心脏疾病,包括心肌梗死、心律失常、心力衰竭和心脏性猝死。在过去的几十年中,大多数关于细胞死亡的研究都集中在细胞凋亡上,细胞凋亡通常被认为是唯一形式的受调控的细胞死亡,而坏死则被认为是一种不受调控的过程。最近的发现揭示了坏死也以受调控的方式发生,并且与包括心脏在内的许多器官的生理学和病理生理学密切相关。坏死被认为是一种受调控的过程,这就要求重新审视心脏中的细胞死亡以及心脏疾病的机制和治疗方法。在本研究中,我们总结了心肌细胞程序性坏死的调节机制,即内在(线粒体)和外在(死亡受体)途径。此外,还描述了这种程序性坏死在各种心脏疾病中的作用。最后,我们描述了几种调控细胞坏死的关键调节分子的已知药理学抑制剂及其在心脏疾病治疗中的应用机会。我们旨在系统地总结程序性心肌细胞坏死的调节和病理意义以及其在心脏疾病治疗中的潜在应用的最新进展。

相关文章

本文是关于线粒体药理学的专题部分的一部分:特色机制和治疗转化方法。要查看本部分中的其他文章,请访问 http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.22/issuetoc.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb62/6887687/d859a1659a77/BPH-176-4319-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb62/6887687/08da7990a591/BPH-176-4319-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb62/6887687/d859a1659a77/BPH-176-4319-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb62/6887687/08da7990a591/BPH-176-4319-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb62/6887687/d859a1659a77/BPH-176-4319-g002.jpg

相似文献

1
Programmed necrosis in cardiomyocytes: mitochondria, death receptors and beyond.心肌细胞程序性坏死:线粒体、死亡受体及其他。
Br J Pharmacol. 2019 Nov;176(22):4319-4339. doi: 10.1111/bph.14363. Epub 2018 Jun 25.
2
Mitochondrial function in the heart: the insight into mechanisms and therapeutic potentials.心脏中的线粒体功能:对机制和治疗潜力的深入了解。
Br J Pharmacol. 2019 Nov;176(22):4302-4318. doi: 10.1111/bph.14431. Epub 2018 Aug 2.
3
Inhibiting nucleolin reduces inflammation induced by mitochondrial DNA in cardiomyocytes exposed to hypoxia and reoxygenation.抑制核仁素可减少低氧和再复氧诱导的心肌细胞中线粒体 DNA 引起的炎症。
Br J Pharmacol. 2019 Nov;176(22):4360-4372. doi: 10.1111/bph.14830. Epub 2019 Oct 27.
4
Mitochondrial pharmacology: featured mechanisms and approaches for therapy translation.线粒体药理学:治疗转化的特色机制和方法。
Br J Pharmacol. 2019 Nov;176(22):4245-4246. doi: 10.1111/bph.14820.
5
Role of apoptosis in cardiovascular disease.细胞凋亡在心血管疾病中的作用。
Apoptosis. 2009 Apr;14(4):536-48. doi: 10.1007/s10495-008-0302-x.
6
Cell death in the myocardium: my heart won't go on.心肌细胞死亡:我的心将不再跳动。
IUBMB Life. 2013 Aug;65(8):651-6. doi: 10.1002/iub.1180. Epub 2013 Jul 3.
7
Role of cell death in the progression of heart failure.细胞死亡在心力衰竭进展中的作用。
Heart Fail Rev. 2016 Mar;21(2):157-67. doi: 10.1007/s10741-016-9532-0.
8
Role of noncoding RNAs in regulation of cardiac cell death and cardiovascular diseases.非编码 RNA 在心脏细胞死亡和心血管疾病中的调控作用。
Cell Mol Life Sci. 2018 Jan;75(2):291-300. doi: 10.1007/s00018-017-2640-8. Epub 2017 Sep 14.
9
Molecular mechanism and therapy application of necrosis during myocardial injury.心肌损伤过程中细胞坏死的分子机制与治疗应用。
J Cell Mol Med. 2018 May;22(5):2547-2557. doi: 10.1111/jcmm.13575. Epub 2018 Mar 1.
10
Programmed death of cardiomyocytes in cardiovascular disease and new therapeutic approaches.心肌细胞程序性死亡在心血管疾病中的作用及新的治疗方法。
Pharmacol Res. 2024 Aug;206:107281. doi: 10.1016/j.phrs.2024.107281. Epub 2024 Jun 26.

引用本文的文献

1
Cardiomyocyte regeneration after infarction: changes, opportunities and challenges.心肌梗死后的心肌细胞再生:变化、机遇与挑战。
Mol Cell Biochem. 2025 Mar 17. doi: 10.1007/s11010-025-05251-w.
2
The Cardiomyocyte in Cirrhosis: Pathogenic Mechanisms Underlying Cirrhotic Cardiomyopathy.肝硬化中的心肌细胞:肝硬化性心肌病的发病机制
Rev Cardiovasc Med. 2024 Dec 24;25(12):457. doi: 10.31083/j.rcm2512457. eCollection 2024 Dec.
3
Mechanistic elucidation of ferroptosis and ferritinophagy: implications for advancing our understanding of arthritis.

本文引用的文献

1
Necrostatin-1 Protects Against Paraquat-Induced Cardiac Contractile Dysfunction via RIP1-RIP3-MLKL-Dependent Necroptosis Pathway.Necrostatin-1 通过 RIP1-RIP3-MLKL 依赖性坏死通路保护百草枯诱导的心脏收缩功能障碍。
Cardiovasc Toxicol. 2018 Aug;18(4):346-355. doi: 10.1007/s12012-017-9441-z.
2
Oxidative Stress-Related Parthanatos of Circulating Mononuclear Leukocytes in Heart Failure.心力衰竭患者循环单个核白细胞中与氧化应激相关的 Parthanatos。
Oxid Med Cell Longev. 2017;2017:1249614. doi: 10.1155/2017/1249614. Epub 2017 Nov 9.
3
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY.
铁死亡和铁蛋白自噬的机制阐释:对深化我们对关节炎理解的意义
Front Physiol. 2024 Jul 3;15:1290234. doi: 10.3389/fphys.2024.1290234. eCollection 2024.
4
Trafficking and effect of released DNA on cGAS-STING signaling pathway and cardiovascular disease.释放 DNA 对 cGAS-STING 信号通路的转导作用及其与心血管疾病的关系。
Front Immunol. 2023 Dec 13;14:1287130. doi: 10.3389/fimmu.2023.1287130. eCollection 2023.
5
RIPK1 and RIPK3 inhibitors: potential weapons against inflammation to treat diabetic complications.RIPK1 和 RIPK3 抑制剂:治疗糖尿病并发症的炎症治疗潜在武器。
Front Immunol. 2023 Oct 26;14:1274654. doi: 10.3389/fimmu.2023.1274654. eCollection 2023.
6
The Effects of MicroRNAs in the Development of Heart Failure.微小 RNA 在心力衰竭发展中的作用。
Curr Cardiol Rep. 2023 Jul;25(7):747-759. doi: 10.1007/s11886-023-01895-6. Epub 2023 May 26.
7
Liraglutide Attenuates Myocardial Ischemia/Reperfusion Injury Through the Inhibition of Necroptosis by Activating GLP-1R/PI3K/Akt Pathway.利拉鲁肽通过激活GLP-1R/PI3K/Akt通路抑制坏死性凋亡减轻心肌缺血/再灌注损伤。
Cardiovasc Toxicol. 2023 Apr;23(3-4):161-175. doi: 10.1007/s12012-023-09789-3. Epub 2023 Mar 19.
8
Glutathione system enhancement for cardiac protection: pharmacological options against oxidative stress and ferroptosis.谷胱甘肽系统增强在心脏保护中的作用:抗氧化应激和铁死亡的药理学选择。
Cell Death Dis. 2023 Feb 16;14(2):131. doi: 10.1038/s41419-023-05645-y.
9
A Self-Sustaining Antioxidant Strategy for Effective Treatment of Myocardial Infarction.一种自维持抗氧化策略,用于有效治疗心肌梗死。
Adv Sci (Weinh). 2023 Feb;10(5):e2204999. doi: 10.1002/advs.202204999. Epub 2022 Dec 25.
10
Necroptosis: A Pathogenic Negotiator in Human Diseases.细胞坏死性凋亡:人类疾病中的一种致病谈判者。
Int J Mol Sci. 2022 Oct 22;23(21):12714. doi: 10.3390/ijms232112714.
2018 年 IUPHAR/BPS 药理学指南:更新和扩展,以包含新的免疫药理学指南。
Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106. doi: 10.1093/nar/gkx1121.
4
Protective effects of the mechanistic target of rapamycin against excess iron and ferroptosis in cardiomyocytes.雷帕霉素靶蛋白的保护作用可抵抗心肌细胞中的铁过载和铁死亡。
Am J Physiol Heart Circ Physiol. 2018 Mar 1;314(3):H659-H668. doi: 10.1152/ajpheart.00452.2017. Epub 2017 Nov 10.
5
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Transporters.2017/18 年药理学简明指南:转运蛋白。
Br J Pharmacol. 2017 Dec;174 Suppl 1(Suppl Suppl 1):S360-S446. doi: 10.1111/bph.13883.
6
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes.《药理学简明指南 2017/18:酶》
Br J Pharmacol. 2017 Dec;174 Suppl 1(Suppl Suppl 1):S272-S359. doi: 10.1111/bph.13877.
7
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Nuclear hormone receptors.2017/18 年简明药理学指南:核激素受体。
Br J Pharmacol. 2017 Dec;174 Suppl 1(Suppl Suppl 1):S208-S224. doi: 10.1111/bph.13880.
8
Necroptosis may be a novel mechanism for cardiomyocyte death in acute myocarditis.细胞程序性坏死可能是急性心肌炎中心肌细胞死亡的一种新机制。
Mol Cell Biochem. 2018 May;442(1-2):11-18. doi: 10.1007/s11010-017-3188-5. Epub 2017 Sep 8.
9
PPAR- Activation Prevents Septic Cardiac Dysfunction via Inhibition of Apoptosis and Necroptosis.过氧化物酶体增殖物激活受体-γ激活通过抑制凋亡和坏死性凋亡预防脓毒症性心脏功能障碍。
Oxid Med Cell Longev. 2017;2017:8326749. doi: 10.1155/2017/8326749. Epub 2017 Aug 3.
10
Ellagic acid antagonizes Bnip3-mediated mitochondrial injury and necrotic cell death of cardiac myocytes.鞣花酸拮抗 Bnip3 介导的心肌细胞线粒体损伤和坏死性细胞死亡。
Free Radic Biol Med. 2017 Nov;112:411-422. doi: 10.1016/j.freeradbiomed.2017.08.010. Epub 2017 Aug 30.